ストックスクリーナーアプリを入手
4.17
8.88%
0.34
アフターアワーズ：
4.17
前日終値:
$3.83
開ける：
$3.97
24時間の取引高:
1.55M
Relative Volume:
0.47
時価総額：
$475.10M
収益：
$884.00K
当期純損益:
$-103.64M
株価収益率:
-2.9905
EPS:
-1.3944
ネットキャッシュフロー:
$-95.45M
1週間 パフォーマンス:
-2.80%
1か月 パフォーマンス:
-22.78%
6か月 パフォーマンス:
+21.57%
1年 パフォーマンス:
+95.77%
1日の値動き範囲:
$3.97
$4.29
1週間の範囲:
$3.81
$4.60
52週間の値動き範囲:
$1.60
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
名前
Perspective Therapeutics Inc
セクター
電話
509-375-1202
住所
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.17 | 436.37M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-19 | 開始されました | Piper Sandler | Overweight |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-10-10 | 開始されました | BTIG Research | Buy |
| 2025-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-01 | 開始されました | Wedbush | Outperform |
| 2024-09-25 | 開始されました | Truist | Buy |
| 2024-07-25 | 開始されました | BofA Securities | Buy |
| 2024-05-09 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Perspective Therapeutics Inc (CATX) 最新ニュース
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
If You Invested $1,000 in Perspective Therapeutics Inc (CATX) - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CATX Should I Buy - Intellectia AI
Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M - MarketBeat
Jones Trading reiterates Perspective Therapeutics stock Buy rating By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Jones Trading reiterates Perspective Therapeutics stock Buy rating - Investing.com
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | CATX Stock News - GuruFocus
B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price - MarketBeat
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | - GuruFocus
Perspective Therapeutics (CATX) Receives Boost from UBS with Rai - GuruFocus
Perspective Therapeutics price target raised to $13 from $11 at B. Riley - TipRanks
UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating - marketscreener.com
UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock - MarketBeat
Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating - marketscreener.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 - The Manila Times
Perspective Therapeutics (CATX) to Release Earnings on Wednesday - MarketBeat
RBC cuts Perspective Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Perspective Therapeutics Q4 2025 earnings preview - MSN
Truist reiterates Buy on Perspective Therapeutics stock By Investing.com - Investing.com Canada
BTIG Reiterates Buy Rating for CATX with $14 Price Target | CATX Stock News - GuruFocus
Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00 - MarketBeat
RBC Capital Lowers Price Target for CATX While Maintaining 'Outp - GuruFocus
Truist reiterates Buy on Perspective Therapeutics stock - Investing.com
RBC cuts Perspective Therapeutics stock price target on model updates - Investing.com
Perspective Therapeutics stock rating reiterated at Buy by BTIG - Investing.com South Africa
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform By Investing.com - Investing.com South Africa
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives "Buy" Rating from BTIG Research - MarketBeat
RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk - marketscreener.com
Perspective Therapeutics, Inc. 2025 10-K Report: Advancing Targeted Alpha Therapy Radiopharmaceuticals for Cancer Treatment - minichart.com.sg
Perspective Therapeutics Inc (CATX) 財務データ
収益
当期純利益
現金流量
EPS
2.03%
大文字化:
|
ボリューム (24 時間):